Trial Profile
A multicenter, randomized, controlled trial of S-1 vs. Gemcitabine for treatment of untreated advanced pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Sep 2018
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 25 May 2016 New trial record